Citations

Clear

382 citation(s) found for "Shapiro, CL".

Faculty Opinions recommendation of Redefining thymus medulla specialization for central tolerance.
Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 8, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.729083339.793541013 Get It

Snapping Pes Anserinus and the Diagnostic Utility of Dynamic Ultrasound
Hernandez, Lorenzo O., Montero, Daniel , Montero, Daniel P, Shapiro, Shane A.

Mayo Clinic

Journal of Clinical Imaging Science | October 17, 2017 | Volume: 7 | Issue: No issue available | Pages: 39

10.4103/jcis.jcis_45_17 | PMID 29142781 Get It

Snapping pes anserinus syndrome is an often encountered cause of medial knee snapping. It results from impingement and translation of the gracilis tendon or semitendinosus tendon over the osseous structures of the knee during active flexion and extension. Ultrasonography is often the diagnostic imaging test of choice in cases of mechanical snapping. We report 2 cases of painful snapping pes anserinus and highlight the value of dynamic ultrasound in making an accurate diagnosis so as to direct care.
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)
Moriarty, James P. , Dusetzina, Stacie B. , Himelstein, Andrew L., Foster, Jared C. , Grubbs, Stephen S., Novotny, Paul J. , Shapiro, Charles L. , Dusetzina, Stacie, Borah, Bijan J. , Dusetzina, Stacie

Mayo Clinic

Journal of Clinical Oncology | October 12, 2017 | Volume: 35 | Issue: 35 | Pages: 3949-3955

10.1200/jco.2017.73.7437 | PMID 29023215 Get It

Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases. Methods Using a Markov model, costs per SRE avoided were calculated for the three treatments. Sensitivity analyses were performed where denosumab SRE probabilities were assumed to be 50%, 75%, and 90% lower than the ZA SRE probabilities. Quality-adjusted life-years were also calculated. The analysis was from the US payer perspective. Results The mean costs of the denosumab treatment strategy are nine-fold higher than generic ZA every 3 months. Quality-adjusted life-years were virtually identical in all the three treatment arms; hence, the optimal treatment would be ZA every 3 months because it was the least costly treatment. The sensitivity analyses showed that relative to ZA every 3 months, the incremental costs per mean SRE avoided for denosumab ranged from $162,918 to $347,655. Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab. This analysis was one of the first to incorporate the costs of generic ZA and one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively. ZA every 3 months is the more CE option and more reasonable alternative to monthly denosumab.
Faculty Opinions recommendation of Cutting edge: dual tcrα expression poses an autoimmune hazard by limiting regulatory T cell generation.
Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727650337.793536656 Get It

Bone Marrow Aspiration for Regenerative Orthopedic Intervention: Technique with Ultrasound Guidance for Needle Placement
Arthurs, Jennifer R. , Shapiro, Shane A.

Mayo Clinic

Regenerative Medicine | September 11, 2017 | Volume: 12 | Issue: 8 | Pages: 917-928

10.2217/rme-2017-0109 | PMID 28891421 Get It

Well-Being in Graduate Medical Education: A Call for Action
Ripp, Jonathan A., Privitera, Michael R. , Leiter, Richard E. , Logio, Lia , Shapiro, Jo , Bazari, Hasan, West, Colin P.

Mayo Clinic

Academic Medicine | May 3, 2017 | Volume: 92 | Issue: 7 | Pages: 914-917

10.1097/acm.0000000000001735 | PMID 28471780 Get It

Job burnout is highly prevalent in graduate medical trainees. Numerous demands and stressors drive the development of burnout in this population, leading to significant and potentially tragic consequences, not only for trainees but also for the patients and communities they serve. The literature on interventions to reduce resident burnout is limited but suggests that both individual- and system-level approaches are effective. Work hours limitations and mindfulness training are each likely to have modest benefit. Despite concerns that physician trainee wellness programs might be costly, attention to physician wellness may lead to important benefits such as greater patient satisfaction, long-term physician satisfaction, and increased physician productivity. A collaborative of medical educators, academic leaders, and researchers recently formed with the goal of improving trainee well-being and mitigating burnout. Its first task is outlining this framework of initial recommendations in a call to action. These recommendations are made at the national, hospital, program, and nonwork levels and are meant to inform stakeholders who have taken up the charge to address trainee well-being. Regulatory bodies and health care systems need to be accountable for the well-being of trainees under their supervision and drive an enforceable mandate to programs under their charge. Programs and individuals should develop and engage in a “menu” of wellness options to reach a variety of learners and standardize the effort to ameliorate burnout. The impact of these multilevel changes will promote a culture where trainees can learn in settings that will sustain them over the course of their careers.
Zoledronic Acid Dosing Interval for Metastatic Cancer—Reply
Himelstein, Andrew L., Loprinzi, Charles L. , Shapiro, Charles L.

Mayo Clinic

JAMA | April 11, 2017 | Volume: 317 | Issue: 14 | Pages: 1478

10.1001/jama.2017.2566 | PMID 28399247 Get It

Prognostic value of cell cycle regulators p27 and cyclin E: Tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313
Porter, Peggy L. , Yeh, I‐Tien, Lin, M.‐G., Yuan, X., Shapiro, CL, Sledge, G. P., Livingston, R. B., Hayes, Daniel F. , Barlow, William E. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 507-507

10.1200/jco.2005.23.16_suppl.507 Get It

Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial
Becske, Tibor , Brinjikji, Waleed , Potts, Matthew B. , Kallmes, David F. , Shapiro, Maksim , Moran, Christopher J. , McDougall, Cameron G. , Szikora, István , Woo, Henry H. , Siddiqui, Adnan H. , Albuquerque, Felipe C. , Saatçi, Işıl , Cekirge, Saruhan H., Berez, Aaron L., Cher, Daniel , Berentei, Zsolt, Nelson, Peter K. , Levy, Elad I. , Lanzino, Giuseppe , Lopes, Demetrius K. , Fiorella, David , Marosföi, Miklós , Siddiqui, Adnan H , Szikora, Istvan

Mayo Clinic

Neurosurgery | February 5, 2017 | Volume: 80 | Issue: 1 | Pages: 40-48

10.1093/neuros/nyw014 | PMID 28362885 Get It

Abstract BACKGROUND: Early and mid-term safety and efficacy of aneurysm treatment with the Pipeline Embolization Device (PED) has been well demonstrated in prior studies. OBJECTIVE: To present 5-yr follow-up for patients treated in the Pipeline for Uncoilable or Failed Aneurysms clinical trial. METHODS: In our prospective, multicenter trial, 109 complex internal carotid artery (ICA) aneurysms in 107 subjects were treated with the PED. Patients were followed per a standardized protocol at 180 d and 1, 3, and 5 yr. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale scores, and complications were recorded. RESULTS: The primary endpoint of complete aneurysm occlusion at 180 d (73.6%) was previously reported. Aneurysm occlusion for those patients with angiographic follow-up progressively increased over time to 86.8% (79/91), 93.4% (71/76), and 95.2% (60/63) at 1, 3, and 5 yr, respectively. Six aneurysms (5.7%) were retreated. New serious device-related events at 1, 3, and 5 yr were noted in 1% (1/96), 3.5% (3/85), and 0% (0/81) of subjects. There were 4 (3.7%) reported deaths in our trial. Seventy-eight (96.3%) of 81 patients with 5-yr clinical follow-up had modified Rankin Scale scores ≤2. No delayed neurological deaths or hemorrhagic or ischemic cerebrovascular events were reported beyond 6 mo. No recanalization of a previously occluded aneurysm was observed. CONCLUSION: Our 5-yr findings demonstrate that PED is a safe and effective treatment for large and giant wide-necked aneurysms of the intracranial ICA, with high rates of complete occlusion and low rates of delayed adverse events.
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
Himelstein, Andrew L., Foster, Jared C. , Khatcheressian, James, Roberts, John D. , Seisler, Drew K., Novotny, Paul J. , Qin, Rui , Grubbs, Stephen S., O’Connor, Tracey L. , Velasco, Mario R. , Weckstein, Douglas, O’Mara, Ann M., Loprinzi, Charles L. , Go, Ronald S. , Shapiro, Charles L.

Mayo Clinic

JAMA | January 5, 2017 | Volume: 317 | Issue: 1 | Pages: 48

10.1001/jama.2016.19425 | PMID 28030702 Get It